Delving into the Latest Updates on Melcure SA (Switzerland) with Synapse

概览

关联

1

项与 Melcure SA (Switzerland) 相关的药物

BQ-788

靶点

ETB

作用机制

ETB拮抗剂

在研机构-

原研机构

Merck Serono SA

在研适应症-

非在研适应症

高血压 [+1]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

1

项与 Melcure SA (Switzerland) 相关的临床试验

NCT02442466

/ Terminated早期临床1期

Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma

Intra-lesion administration of an Endothelin Receptor B inhibitor (BQ-788) or vehicle was preformed in 5 melanoma patients to have a preliminary analysis of safety, dose, duration and relevance of results observed in pre-clinical studies to the human disease.

开始日期2011-05-01

申办/合作机构

Melcure SA (Switzerland)

[+3]

100 项与 Melcure SA (Switzerland) 相关的临床结果

登录后查看更多信息

0 项与 Melcure SA (Switzerland) 相关的专利（医药）

登录后查看更多信息

100 项与 Melcure SA (Switzerland) 相关的药物交易

登录后查看更多信息

100 项与 Melcure SA (Switzerland) 相关的转化医学

登录后查看更多信息